Werewolf Therapeutics Inc

NASDAQ HOWL

Data sourced from

and

Daily

Download Data

Werewolf Therapeutics Inc Price to Earnings Ratio (P/E) on June 03, 2024: -34.01

Werewolf Therapeutics Inc Price to Earnings Ratio (P/E) is -34.01 on June 03, 2024, a -1,368.04% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Werewolf Therapeutics Inc 52-week high Price to Earnings Ratio (P/E) is -1.74 on September 26, 2023, which is 94.89% above the current Price to Earnings Ratio (P/E).
Werewolf Therapeutics Inc 52-week low Price to Earnings Ratio (P/E) is -52.31 on April 30, 2024, which is -53.81% below the current Price to Earnings Ratio (P/E).
Werewolf Therapeutics Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -9.33.

NASDAQ: HOWL

Werewolf Therapeutics Inc

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue, Cambridge, MA, United States, 02138
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Key trends